308 related articles for article (PubMed ID: 29438260)
41. [Rendu-Osler disease: clinical and molecular update].
Bailly S; Dupuis-Girod S; Plauchu H
Med Sci (Paris); 2010 Oct; 26(10):855-60. PubMed ID: 20929677
[TBL] [Abstract][Full Text] [Related]
42. Functional analysis of endoglin mutations from hereditary hemorrhagic telangiectasia type 1 patients reveals different mechanisms for endoglin loss of function.
Mallet C; Lamribet K; Giraud S; Dupuis-Girod S; Feige JJ; Bailly S; Tillet E
Hum Mol Genet; 2015 Feb; 24(4):1142-54. PubMed ID: 25312062
[TBL] [Abstract][Full Text] [Related]
43. Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia.
Albiñana V; Recio-Poveda L; Zarrabeitia R; Bernabéu C; Botella LM
Thromb Haemost; 2012 Jul; 108(1):41-53. PubMed ID: 22552254
[TBL] [Abstract][Full Text] [Related]
44. Enhanced responses to angiogenic cues underlie the pathogenesis of hereditary hemorrhagic telangiectasia 2.
Choi EJ; Kim YH; Choe SW; Tak YG; Garrido-Martin EM; Chang M; Lee YJ; Oh SP
PLoS One; 2013; 8(5):e63138. PubMed ID: 23675457
[TBL] [Abstract][Full Text] [Related]
45. Hereditary haemorrhagic telangiectasia: a clinical and scientific review.
Govani FS; Shovlin CL
Eur J Hum Genet; 2009 Jul; 17(7):860-71. PubMed ID: 19337313
[TBL] [Abstract][Full Text] [Related]
46. Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia.
Tillet E; Bailly S
Front Genet; 2014; 5():456. PubMed ID: 25620979
[TBL] [Abstract][Full Text] [Related]
47. Mutations causing premature termination codons discriminate and generate cellular and clinical variability in HHT.
Bernabéu-Herrero ME; Patel D; Bielowka A; Zhu J; Jain K; Mackay IS; Chaves Guerrero P; Emanuelli G; Jovine L; Noseda M; Marciniak SJ; Aldred MA; Shovlin CL
Blood; 2024 May; 143(22):2314-2331. PubMed ID: 38457357
[TBL] [Abstract][Full Text] [Related]
48. Impact of heterozygous ALK1 mutations on the transcriptomic response to BMP9 and BMP10 in endothelial cells from hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension donors.
Al Tabosh T; Liu H; Koça D; Al Tarrass M; Tu L; Giraud S; Delagrange L; Beaudoin M; Rivière S; Grobost V; Rondeau-Lutz M; Dupuis O; Ricard N; Tillet E; Machillot P; Salomon A; Picart C; Battail C; Dupuis-Girod S; Guignabert C; Desroches-Castan A; Bailly S
Angiogenesis; 2024 May; 27(2):211-227. PubMed ID: 38294582
[TBL] [Abstract][Full Text] [Related]
49. Novel brain arteriovenous malformation mouse models for type 1 hereditary hemorrhagic telangiectasia.
Choi EJ; Chen W; Jun K; Arthur HM; Young WL; Su H
PLoS One; 2014; 9(2):e88511. PubMed ID: 24520391
[TBL] [Abstract][Full Text] [Related]
50. Brain arteriovenous malformation in hereditary hemorrhagic telangiectasia: Recent advances in cellular and molecular mechanisms.
Drapé E; Anquetil T; Larrivée B; Dubrac A
Front Hum Neurosci; 2022; 16():1006115. PubMed ID: 36504622
[TBL] [Abstract][Full Text] [Related]
51. Mutation analysis in hereditary haemorrhagic telangiectasia in Germany reveals 11 novel ENG and 12 novel ACVRL1/ALK1 mutations.
Wehner LE; Folz BJ; Argyriou L; Twelkemeyer S; Teske U; Geisthoff UW; Werner JA; Engel W; Nayernia K
Clin Genet; 2006 Mar; 69(3):239-45. PubMed ID: 16542389
[TBL] [Abstract][Full Text] [Related]
52. ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2.
Park SO; Lee YJ; Seki T; Hong KH; Fliess N; Jiang Z; Park A; Wu X; Kaartinen V; Roman BL; Oh SP
Blood; 2008 Jan; 111(2):633-42. PubMed ID: 17911384
[TBL] [Abstract][Full Text] [Related]
53. Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies.
Nolan-Stevaux O; Zhong W; Culp S; Shaffer K; Hoover J; Wickramasinghe D; Ruefli-Brasse A
PLoS One; 2012; 7(12):e50920. PubMed ID: 23300529
[TBL] [Abstract][Full Text] [Related]
54. Executive summary of the 11th HHT international scientific conference.
Arthur H; Geisthoff U; Gossage JR; Hughes CC; Lacombe P; Meek ME; Oh P; Roman BL; Trerotola SO; Velthuis S; Wooderchak-Donahue W
Angiogenesis; 2015 Oct; 18(4):511-24. PubMed ID: 26391603
[TBL] [Abstract][Full Text] [Related]
55. Induced Endothelial Cell Cycle Arrest Prevents Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia.
Genet G; Genet N; Paila U; Cain SR; Cwiek A; Chavkin NW; Serbulea V; Figueras A; Cerdà P; McDonnell SP; Sankaranarayanan D; Huba M; Nelson EA; Riera-Mestre A; Hirschi KK
Circulation; 2024 Mar; 149(12):944-962. PubMed ID: 38126211
[TBL] [Abstract][Full Text] [Related]
56. Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells.
Upton PD; Davies RJ; Trembath RC; Morrell NW
J Biol Chem; 2009 Jun; 284(23):15794-804. PubMed ID: 19366699
[TBL] [Abstract][Full Text] [Related]
57. Key role of the endothelial TGF-β/ALK1/endoglin signaling pathway in humans and rodents pulmonary hypertension.
Gore B; Izikki M; Mercier O; Dewachter L; Fadel E; Humbert M; Dartevelle P; Simonneau G; Naeije R; Lebrin F; Eddahibi S
PLoS One; 2014; 9(6):e100310. PubMed ID: 24956016
[TBL] [Abstract][Full Text] [Related]
58. An update on preclinical models of hereditary haemorrhagic telangiectasia: Insights into disease mechanisms.
Arthur HM; Roman BL
Front Med (Lausanne); 2022; 9():973964. PubMed ID: 36250069
[TBL] [Abstract][Full Text] [Related]
59. Immunosuppressor FK506 increases endoglin and activin receptor-like kinase 1 expression and modulates transforming growth factor-β1 signaling in endothelial cells.
Albiñana V; Sanz-Rodríguez F; Recio-Poveda L; Bernabéu C; Botella LM
Mol Pharmacol; 2011 May; 79(5):833-43. PubMed ID: 21310938
[TBL] [Abstract][Full Text] [Related]
60. PI3K (Phosphatidylinositol 3-Kinase) Activation and Endothelial Cell Proliferation in Patients with Hemorrhagic Hereditary Telangiectasia Type 1.
Iriarte A; Figueras A; Cerdà P; Mora JM; Jucglà A; Penín R; Viñals F; Riera-Mestre A
Cells; 2019 Aug; 8(9):. PubMed ID: 31450639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
